The Novo Nordisk and Hims Deal: What It Means for GLP-1 Pricing and Access
Author
glp winnerDate Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
Novo Nordisk and Hims & Hers reached a deal that lets Hims sell FDA-approved Ozempic, Wegovy, and the new Wegovy pill at lower self-pay prices, and it could shift how millions of people access and pay for GLP-1 medications going forward.
Who This Helps
This article is for anyone currently taking or considering a GLP-1 medication, a type of medicine that helps with weight management or blood sugar control by mimicking a natural hormone in your body. Whether you are on a branded FDA-approved product, a compounded GLP-1 product, or just starting to explore your options, this deal changes the pricing picture. It also helps anyone trying to understand why this partnership happened and what it means for the broader GLP-1 market.
GLP Winner helps you compare providers and pricing across the telehealth space so you can see where this deal fits into your options.
What Happened Between Novo Nordisk and Hims
Novo Nordisk, the company behind Ozempic and Wegovy, dropped its patent lawsuit against Hims & Hers (PBS News). In exchange, the two companies entered a collaboration.
Under the deal, Hims will sell multiple doses of both injectable and oral forms of Novo's FDA-approved GLP-1 medications. That includes Ozempic, Wegovy injectables, and the newly launched Wegovy pill (Hims & Hers Investor Relations).
In return, Hims agreed to stop advertising compounded GLP-1 products on its platform and in its marketing (CNBC). Existing patients on compounded GLP-1 products through Hims will have the chance to transition to FDA-approved options with guidance from their provider.
Novo is also reserving the right to refile the patent lawsuit in the future (Fierce Pharma).
What this means for you: This is the first major deal between a pharmaceutical company and a large telehealth platform in the GLP-1 space. It signals a shift toward lower branded pricing and more direct-to-consumer access for FDA-approved products.
Why This Deal Happened Now
The timing was not random. Several things lined up at once.
Novo Nordisk's stock had dropped to 2021 levels (PBS News). Hims & Hers was facing growing legal and regulatory pressure. And the FDA had just issued warning letters to 30 telehealth companies for making misleading claims about compounded GLP-1 products (FDA).
Sabina Hemmi, co-founder of GLP Winner, posted a TikTok breakdown right after the news broke. She pointed out that both companies had strong financial reasons to partner. Hims stock jumped about 40% on the announcement. Novo stock moved up roughly 2.5%.
As Sabina put it, the deal benefits shareholders on both sides. The FDA gets to see a major telehealth company shift toward FDA-approved products. And both companies get a public win that eases regulatory tension.
If you are comparing how different providers are responding to this shift, GLP Winner tracks pricing and plan details across platforms so you can see the full picture - including with Hims. Start your comparison here.
What this means for you: The deal was driven by financial and regulatory pressure, not by a change in how GLP-1 medications work or who can prescribe them. The products themselves have not changed.
What the New Pricing Looks Like
Here is what the self-pay pricing looks like under this deal and through Novo Nordisk's direct pricing programs.
For Wegovy and Ozempic injectables:
- New patients can get an introductory price of $199 per fill for the first two fills (this offer runs through March 31, 2026, so time is running out) (Fierce Pharma)
- This is likely to be updated once the March deadline passes, but stay tuned - After the introductory period, Wegovy costs $349 per month
- Ozempic costs $349 per month for the 0.25mg, 0.5mg, and 1mg doses and $499 per month for the 2mg dose
For the new Wegovy pill:
- The introductory price is $149 per month for the first two months for new patients (BioPharma Dive)
- After that, the price goes to $299 per month
Hims will offer these FDA-approved medications at the same self-pay prices as other telehealth platforms (Hims & Hers Investor Relations).
For context, compounded GLP-1 products on Hims were previously priced at around $199 per month (CNBC). The shift to branded pricing means most patients on the platform will see a price increase for FDA-approved options after introductory periods end.
GLP Winner tracks the latest self-pay pricing across providers so you can see how these numbers stack up. Pricing changes fast, and our comparison tools stay updated.
What this means for you: The introductory prices make FDA-approved GLP-1 products more accessible in the short term. After those promotional periods, monthly costs will be higher than what compounded options typically cost. Comparing across providers matters more than ever.
What This Means for Compounded GLP-1 Access
Hims agreed to stop advertising compounded GLP-1 products. That is a marketing commitment. It does not mean compounded GLP-1 products are going away across the broader market.
Hims stated that providers on its platform can still prescribe compounded GLP-1 products when a provider determines they are necessary for a patient whose needs are not met by available FDA-approved products (Hims & Hers Investor Relations). Compounded GLP-1 products are not FDA-approved as finished drugs (FDA).
The bigger question is whether this deal signals a trend. If more pharmaceutical companies strike similar deals with telehealth platforms, compounded GLP-1 products may become less prominent in marketing across the industry. That does not eliminate them. Licensed compounding pharmacies operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act continue to operate and are subject to state and federal oversight (FDA).
One possible ripple effect: as branded FDA-approved products become more affordable through self-pay programs, compounded GLP-1 pricing may also adjust over time. When higher-priced branded products move closer to what compounded options cost, the entire pricing landscape shifts.
GLP Winner monitors pricing across both FDA-approved and compounded options so you can compare what is available. See current provider pricing here.
What this means for you: Access to compounded GLP-1 products through other providers has not changed because of this deal. Hims is positioning itself as an FDA-first company in its marketing. Prescribers across the industry still make clinical decisions about what is most appropriate for each patient.
The FDA Context Around This Deal
This deal did not happen in a vacuum. The FDA has been increasing its enforcement activity in the GLP-1 space.
In early March 2026, the FDA issued warning letters to 30 telehealth companies for making misleading claims about compounded GLP-1 products (FDA). The letters focused on companies that implied their compounded products were equivalent to FDA-approved drugs or that obscured where their products were actually coming from.
In February 2026, the FDA announced its intention to take action against companies marketing non-FDA-approved GLP-1 products as "generic," "the same as," or made with "the same active ingredient" as FDA-approved drugs (FDA).
FDA Commissioner Marty Makary stated that the agency is watching marketing claims across all media platforms (FDA). The agency has sent more warning letters in the past six months than it had in the entire preceding decade (BioSpace).
The Novo Nordisk and Hims deal gives the FDA a visible example of a major telehealth company shifting its public approach. As Sabina Hemmi noted in her TikTok breakdown, the FDA expressed satisfaction with the direction of the deal. That matters for the broader regulatory tone, but it does not change the legal frameworks that govern compounding.
How This Could Affect the Broader GLP-1 Market
This deal sets a precedent. Whether other pharmaceutical companies follow with similar telehealth partnerships is something to watch.
Eli Lilly, the company behind Mounjaro and Zepbound, has not announced a similar deal with any telehealth platform as of this writing (BioPharma Dive). But the competitive pressure is real. If Novo Nordisk's self-pay pricing through Hims drives patient volume, other manufacturers may respond with their own pricing programs or partnerships.
The pricing dynamic is worth paying attention to. Before this deal, the landscape looked roughly like this:
- Compounded GLP-1 products through telehealth: around $199 per month
- FDA-approved branded products at full list price: $1,000 or more per month
- FDA-approved branded products through new self-pay programs: $149 to $499 per month depending on the product and dose
That middle ground is new. It did not exist a year ago. And it changes the math for a lot of people.
GLP Winner's provider comparison tools help you see how pricing is shifting in real time across the market. Whether you are exploring FDA-approved brands, compounded options, or both, understanding the full pricing picture is the first step.
Final Takeaway
The GLP-1 market just shifted in a way that benefits people looking for more affordable access to FDA-approved medications.
The deal between Novo Nordisk and Hims opens a new pricing tier that did not exist before. Your options are growing, not shrinking. Compounded GLP-1 products through other providers remain available. FDA-approved brands are becoming more reachable through self-pay pricing. The most useful thing you can do right now is compare what is available to you.
Take your time. Talk to a provider. And make the choice that fits your health and your budget.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Sources
Keep Reading
GLP-1 shots cost under $5 to make but sell for $900+. See what drives the price, whether it's justified, and how pricing is changing in 2026.
India’s GLP-1 patent expiry may lower prices there first. Learn what it could mean for US access and affordability.
Learn how GLP-1 insurance coverage works, including prior authorization, appeals, step therapy, and patient responsibilities.
Proposed state and federal compounding laws could affect GLP-1 access in 2026. Here’s what’s changing and why it matters.
Curated by
